Loading…
Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer
Purpose Gallbladder and pancreas share common embryological origin, and malignancies of these organs may share common tumor antigens. CA 242 is a tumor marker for pancreatic cancer, but has not been studied in gallbladder cancer (GBC). We measured serum CA 242 levels in patients with GBC and compare...
Saved in:
| Published in: | Journal of gastrointestinal cancer 2012-06, Vol.43 (2), p.267-271 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3257-69781537ffd2d023e84352c4d2ccda0f2492558f093fdec83afe07c12f59fb353 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3257-69781537ffd2d023e84352c4d2ccda0f2492558f093fdec83afe07c12f59fb353 |
| container_end_page | 271 |
| container_issue | 2 |
| container_start_page | 267 |
| container_title | Journal of gastrointestinal cancer |
| container_volume | 43 |
| creator | Rana, Surinder Dutta, Usha Kochhar, Rakesh Rana, Satyavati V. Gupta, Rajesh Pal, Ravinder Jain, Kapil Srinivasan, Radhika Nagi, Birender Nain, Chander Kant Singh, Kartar |
| description | Purpose
Gallbladder and pancreas share common embryological origin, and malignancies of these organs may share common tumor antigens. CA 242 is a tumor marker for pancreatic cancer, but has not been studied in gallbladder cancer (GBC). We measured serum CA 242 levels in patients with GBC and compared it with those in patients with gallstones (GS) and healthy volunteers.
Methods
We enrolled consecutive patients with GBC (cases), GS (disease controls), and healthy volunteers (healthy controls). Serum CA 242, CEA, and CA 19–9 levels were measured using ELISA. Receiver operator curve was plotted for all the three markers.
Results
We studied 117 patients with GBC, 58 with GS, and 10 healthy volunteers. Among patients with GBC, 81 (69%) also had GB calculi. Patients with GBC more often had elevated CA 242 levels (64%) compared to those with GS (17%;
p
|
| doi_str_mv | 10.1007/s12029-011-9288-7 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s12029_011_9288_7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21573879</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3257-69781537ffd2d023e84352c4d2ccda0f2492558f093fdec83afe07c12f59fb353</originalsourceid><addsrcrecordid>eNp9kE9LAzEQxYMotlY_gBfJF1jNTDabBLyUpVah4qWeQ5o_0rrdLYkr-O1dWe3R08ww7z14P0Kugd0CY_IuAzLUBQMoNCpVyBMyBV1CUVW8Oj3uqCbkIucdY1UpAM7JBEFIrqSekvvFp216-7HtWtpFWs8plkhtppau-32X6LNN7yHRbUuXtmk2jfV-OGvbupAuyVm0TQ5Xv3NGXh8W6_qxWL0sn-r5qnAchSwqLRUILmP06BnyoEou0JUenfOWRSw1CqEi0zz64BS3MTDpAKPQccMFnxEYc13qck4hmkPa7m36MsDMDwkzkjADCfNDwsjBczN6Dv1mH_zR8Vd9EOAoyMOrfQvJ7Lo-tUOPf1K_AXtyZnc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer</title><source>Springer Link</source><creator>Rana, Surinder ; Dutta, Usha ; Kochhar, Rakesh ; Rana, Satyavati V. ; Gupta, Rajesh ; Pal, Ravinder ; Jain, Kapil ; Srinivasan, Radhika ; Nagi, Birender ; Nain, Chander Kant ; Singh, Kartar</creator><creatorcontrib>Rana, Surinder ; Dutta, Usha ; Kochhar, Rakesh ; Rana, Satyavati V. ; Gupta, Rajesh ; Pal, Ravinder ; Jain, Kapil ; Srinivasan, Radhika ; Nagi, Birender ; Nain, Chander Kant ; Singh, Kartar</creatorcontrib><description>Purpose
Gallbladder and pancreas share common embryological origin, and malignancies of these organs may share common tumor antigens. CA 242 is a tumor marker for pancreatic cancer, but has not been studied in gallbladder cancer (GBC). We measured serum CA 242 levels in patients with GBC and compared it with those in patients with gallstones (GS) and healthy volunteers.
Methods
We enrolled consecutive patients with GBC (cases), GS (disease controls), and healthy volunteers (healthy controls). Serum CA 242, CEA, and CA 19–9 levels were measured using ELISA. Receiver operator curve was plotted for all the three markers.
Results
We studied 117 patients with GBC, 58 with GS, and 10 healthy volunteers. Among patients with GBC, 81 (69%) also had GB calculi. Patients with GBC more often had elevated CA 242 levels (64%) compared to those with GS (17%;
p
< 0.001) and healthy controls (0%;
p
< 0.001). The median levels of CA 242 was higher in the GBC group (59 [199] U/ml) compared to the GS group (10 [13] U/ml;
p
< 0.001) and the control group (3 [14.5] U/ml;
p
< 0.001). The sensitivity, specificity, positive predictive value (PPV), and negative predictive values of CA 242 for diagnosis of GBC were 64%, 83%, 88%, and 53%, respectively. At a cutoff of 45 U/ml, the specificity and PPV increased to 100%. CA 242 had higher AOC (0.759) compared to CEA (0.528) and CA 19–9 (0.430).
Conclusions
CA 242 is a promising tumor marker for GBC and performs better than CEA and CA 19-9.</description><identifier>ISSN: 1941-6628</identifier><identifier>EISSN: 1941-6636</identifier><identifier>DOI: 10.1007/s12029-011-9288-7</identifier><identifier>PMID: 21573879</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Antigens, Tumor-Associated, Carbohydrate - blood ; Area Under Curve ; Biomarkers, Tumor - blood ; CA-19-9 Antigen - blood ; Cancer Research ; Carcinoembryonic Antigen - blood ; Enzyme-Linked Immunosorbent Assay ; Female ; Gallbladder Neoplasms - blood ; Gastroenterology ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Radiotherapy ; ROC Curve ; Sensitivity and Specificity</subject><ispartof>Journal of gastrointestinal cancer, 2012-06, Vol.43 (2), p.267-271</ispartof><rights>Springer Science+Business Media, LLC 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3257-69781537ffd2d023e84352c4d2ccda0f2492558f093fdec83afe07c12f59fb353</citedby><cites>FETCH-LOGICAL-c3257-69781537ffd2d023e84352c4d2ccda0f2492558f093fdec83afe07c12f59fb353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21573879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rana, Surinder</creatorcontrib><creatorcontrib>Dutta, Usha</creatorcontrib><creatorcontrib>Kochhar, Rakesh</creatorcontrib><creatorcontrib>Rana, Satyavati V.</creatorcontrib><creatorcontrib>Gupta, Rajesh</creatorcontrib><creatorcontrib>Pal, Ravinder</creatorcontrib><creatorcontrib>Jain, Kapil</creatorcontrib><creatorcontrib>Srinivasan, Radhika</creatorcontrib><creatorcontrib>Nagi, Birender</creatorcontrib><creatorcontrib>Nain, Chander Kant</creatorcontrib><creatorcontrib>Singh, Kartar</creatorcontrib><title>Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer</title><title>Journal of gastrointestinal cancer</title><addtitle>J Gastrointest Canc</addtitle><addtitle>J Gastrointest Cancer</addtitle><description>Purpose
Gallbladder and pancreas share common embryological origin, and malignancies of these organs may share common tumor antigens. CA 242 is a tumor marker for pancreatic cancer, but has not been studied in gallbladder cancer (GBC). We measured serum CA 242 levels in patients with GBC and compared it with those in patients with gallstones (GS) and healthy volunteers.
Methods
We enrolled consecutive patients with GBC (cases), GS (disease controls), and healthy volunteers (healthy controls). Serum CA 242, CEA, and CA 19–9 levels were measured using ELISA. Receiver operator curve was plotted for all the three markers.
Results
We studied 117 patients with GBC, 58 with GS, and 10 healthy volunteers. Among patients with GBC, 81 (69%) also had GB calculi. Patients with GBC more often had elevated CA 242 levels (64%) compared to those with GS (17%;
p
< 0.001) and healthy controls (0%;
p
< 0.001). The median levels of CA 242 was higher in the GBC group (59 [199] U/ml) compared to the GS group (10 [13] U/ml;
p
< 0.001) and the control group (3 [14.5] U/ml;
p
< 0.001). The sensitivity, specificity, positive predictive value (PPV), and negative predictive values of CA 242 for diagnosis of GBC were 64%, 83%, 88%, and 53%, respectively. At a cutoff of 45 U/ml, the specificity and PPV increased to 100%. CA 242 had higher AOC (0.759) compared to CEA (0.528) and CA 19–9 (0.430).
Conclusions
CA 242 is a promising tumor marker for GBC and performs better than CEA and CA 19-9.</description><subject>Antigens, Tumor-Associated, Carbohydrate - blood</subject><subject>Area Under Curve</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA-19-9 Antigen - blood</subject><subject>Cancer Research</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Gallbladder Neoplasms - blood</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Radiotherapy</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><issn>1941-6628</issn><issn>1941-6636</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp9kE9LAzEQxYMotlY_gBfJF1jNTDabBLyUpVah4qWeQ5o_0rrdLYkr-O1dWe3R08ww7z14P0Kugd0CY_IuAzLUBQMoNCpVyBMyBV1CUVW8Oj3uqCbkIucdY1UpAM7JBEFIrqSekvvFp216-7HtWtpFWs8plkhtppau-32X6LNN7yHRbUuXtmk2jfV-OGvbupAuyVm0TQ5Xv3NGXh8W6_qxWL0sn-r5qnAchSwqLRUILmP06BnyoEou0JUenfOWRSw1CqEi0zz64BS3MTDpAKPQccMFnxEYc13qck4hmkPa7m36MsDMDwkzkjADCfNDwsjBczN6Dv1mH_zR8Vd9EOAoyMOrfQvJ7Lo-tUOPf1K_AXtyZnc</recordid><startdate>201206</startdate><enddate>201206</enddate><creator>Rana, Surinder</creator><creator>Dutta, Usha</creator><creator>Kochhar, Rakesh</creator><creator>Rana, Satyavati V.</creator><creator>Gupta, Rajesh</creator><creator>Pal, Ravinder</creator><creator>Jain, Kapil</creator><creator>Srinivasan, Radhika</creator><creator>Nagi, Birender</creator><creator>Nain, Chander Kant</creator><creator>Singh, Kartar</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201206</creationdate><title>Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer</title><author>Rana, Surinder ; Dutta, Usha ; Kochhar, Rakesh ; Rana, Satyavati V. ; Gupta, Rajesh ; Pal, Ravinder ; Jain, Kapil ; Srinivasan, Radhika ; Nagi, Birender ; Nain, Chander Kant ; Singh, Kartar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3257-69781537ffd2d023e84352c4d2ccda0f2492558f093fdec83afe07c12f59fb353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antigens, Tumor-Associated, Carbohydrate - blood</topic><topic>Area Under Curve</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA-19-9 Antigen - blood</topic><topic>Cancer Research</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Gallbladder Neoplasms - blood</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Radiotherapy</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rana, Surinder</creatorcontrib><creatorcontrib>Dutta, Usha</creatorcontrib><creatorcontrib>Kochhar, Rakesh</creatorcontrib><creatorcontrib>Rana, Satyavati V.</creatorcontrib><creatorcontrib>Gupta, Rajesh</creatorcontrib><creatorcontrib>Pal, Ravinder</creatorcontrib><creatorcontrib>Jain, Kapil</creatorcontrib><creatorcontrib>Srinivasan, Radhika</creatorcontrib><creatorcontrib>Nagi, Birender</creatorcontrib><creatorcontrib>Nain, Chander Kant</creatorcontrib><creatorcontrib>Singh, Kartar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of gastrointestinal cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rana, Surinder</au><au>Dutta, Usha</au><au>Kochhar, Rakesh</au><au>Rana, Satyavati V.</au><au>Gupta, Rajesh</au><au>Pal, Ravinder</au><au>Jain, Kapil</au><au>Srinivasan, Radhika</au><au>Nagi, Birender</au><au>Nain, Chander Kant</au><au>Singh, Kartar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer</atitle><jtitle>Journal of gastrointestinal cancer</jtitle><stitle>J Gastrointest Canc</stitle><addtitle>J Gastrointest Cancer</addtitle><date>2012-06</date><risdate>2012</risdate><volume>43</volume><issue>2</issue><spage>267</spage><epage>271</epage><pages>267-271</pages><issn>1941-6628</issn><eissn>1941-6636</eissn><abstract>Purpose
Gallbladder and pancreas share common embryological origin, and malignancies of these organs may share common tumor antigens. CA 242 is a tumor marker for pancreatic cancer, but has not been studied in gallbladder cancer (GBC). We measured serum CA 242 levels in patients with GBC and compared it with those in patients with gallstones (GS) and healthy volunteers.
Methods
We enrolled consecutive patients with GBC (cases), GS (disease controls), and healthy volunteers (healthy controls). Serum CA 242, CEA, and CA 19–9 levels were measured using ELISA. Receiver operator curve was plotted for all the three markers.
Results
We studied 117 patients with GBC, 58 with GS, and 10 healthy volunteers. Among patients with GBC, 81 (69%) also had GB calculi. Patients with GBC more often had elevated CA 242 levels (64%) compared to those with GS (17%;
p
< 0.001) and healthy controls (0%;
p
< 0.001). The median levels of CA 242 was higher in the GBC group (59 [199] U/ml) compared to the GS group (10 [13] U/ml;
p
< 0.001) and the control group (3 [14.5] U/ml;
p
< 0.001). The sensitivity, specificity, positive predictive value (PPV), and negative predictive values of CA 242 for diagnosis of GBC were 64%, 83%, 88%, and 53%, respectively. At a cutoff of 45 U/ml, the specificity and PPV increased to 100%. CA 242 had higher AOC (0.759) compared to CEA (0.528) and CA 19–9 (0.430).
Conclusions
CA 242 is a promising tumor marker for GBC and performs better than CEA and CA 19-9.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>21573879</pmid><doi>10.1007/s12029-011-9288-7</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1941-6628 |
| ispartof | Journal of gastrointestinal cancer, 2012-06, Vol.43 (2), p.267-271 |
| issn | 1941-6628 1941-6636 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_s12029_011_9288_7 |
| source | Springer Link |
| subjects | Antigens, Tumor-Associated, Carbohydrate - blood Area Under Curve Biomarkers, Tumor - blood CA-19-9 Antigen - blood Cancer Research Carcinoembryonic Antigen - blood Enzyme-Linked Immunosorbent Assay Female Gallbladder Neoplasms - blood Gastroenterology Humans Internal Medicine Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Radiotherapy ROC Curve Sensitivity and Specificity |
| title | Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T10%3A38%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20CA%20242%20as%20a%20Tumor%20Marker%20in%20Gallbladder%20Cancer&rft.jtitle=Journal%20of%20gastrointestinal%20cancer&rft.au=Rana,%20Surinder&rft.date=2012-06&rft.volume=43&rft.issue=2&rft.spage=267&rft.epage=271&rft.pages=267-271&rft.issn=1941-6628&rft.eissn=1941-6636&rft_id=info:doi/10.1007/s12029-011-9288-7&rft_dat=%3Cpubmed_cross%3E21573879%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3257-69781537ffd2d023e84352c4d2ccda0f2492558f093fdec83afe07c12f59fb353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/21573879&rfr_iscdi=true |